Aurinia and Lonza Enter into Manufacturing Agreement

Aurinia Pharmaceuticals announced on Dec. 19, 2016 that the company has entered into a long-term agreement with Lonza for the manufacture of voclosporin API. This agreement follows a multi-year clinical manufacturing relationship where the companies have refined the process and analytical methods to produce clinical and commercial supplies of voclosporin. Under the terms of the agreement, Lonza will produce cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis (LN) clinical program and for future commercial use. The agreement also provides an option for Lonza to exclusively supply API for up to 20 years.